Qbrelis

The dosage of Lisinopril is highly individualized based on the condition being treated and the patient's response to the medication. Healthcare providers typically follow these standard guidelines:

• Hypertension (High Blood Pressure): The usual starting dose for adults not taking a diuretic is 10 mg once daily. Depending on the blood pressure response, the dose may be increased up to a maximum of 40 mg once daily. Most patients find effective control between 20 mg and 40 mg per day. If a patient is already taking a diuretic, the doctor may stop the diuretic 2-3 days before starting Lisinopril or start with a lower 5 mg dose to prevent a sudden drop in blood pressure.
• Heart Failure: The recommended starting dose is 5 mg once daily. This is often initiated in a controlled medical setting to monitor for hypotension (low blood pressure). The dose is then gradually increased (titrated) over several weeks to a target dose of 20 mg to 40 mg once daily, as tolerated by the patient.
• Post-Myocardial Infarction (Heart Attack): Treatment should ideally begin within 24 hours of the onset of symptoms. The initial dose is 5 mg, followed by another 5 mg after 24 hours, then 10 mg after 48 hours. The maintenance dose is typically 10 mg once daily for at least six weeks.

Lisinopril is approved for the treatment of hypertension in children aged 6 years and older. The dosage is based on body weight:

• Children weighing 20 kg to <50 kg: The starting dose is typically 0.07 mg/kg (up to 5 mg) once daily. The dose can be adjusted by the physician up to a maximum of 20 mg per day.
• Children weighing ≥50 kg: The starting dose is 5 mg once daily, with a maximum dose of 40 mg once daily.
• Note: Lisinopril is not recommended for children under 6 years of age or for children with a glomerular filtration rate (GFR) less than 30 mL/min/1.73m².

Renal Impairment

Since Lisinopril is eliminated entirely by the kidneys, dosage adjustments are critical for patients with renal dysfunction. Healthcare providers use the Creatinine Clearance (CrCl) rate to determine the dose:

• CrCl 10-30 mL/min: Start with 5 mg once daily.
• CrCl <10 mL/min (including dialysis): Start with 2.5 mg once daily. The dose is then carefully titrated based on blood pressure response and renal function monitoring.

Hepatic Impairment

Because Lisinopril is not metabolized by the liver, no specific dosage adjustment is typically required for patients with liver disease. However, these patients should still be monitored closely for overall health status.

Elderly Patients

Older adults may have decreased renal function and a higher sensitivity to the blood-pressure-lowering effects of Lisinopril. Doctors often start at the lower end of the dosing spectrum and monitor for dizziness or lightheadedness when standing (orthostatic hypotension).

• Consistency: Take Lisinopril at the same time every day to maintain steady levels in your bloodstream. Most patients find it easiest to take it in the morning.
• With or Without Food: Lisinopril can be taken with or without food. If it causes stomach upset, taking it with a meal may help.
• Administration: Swallow the tablets whole with a glass of water. If you are using the oral solution, use a calibrated measuring device (not a household spoon) to ensure the correct dose.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F), away from moisture, heat, and direct light.

If you miss a dose of Lisinopril, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not 'double up' or take two doses at once to make up for a missed one, as this increases the risk of severe hypotension.

The most likely symptom of a Lisinopril overdose is severe hypotension (excessively low blood pressure), which can lead to fainting, dizziness, and shock. Other signs may include electrolyte imbalances (such as high potassium) and kidney failure. In the event of a suspected overdose, seek emergency medical attention immediately. Treatment usually involves intravenous fluids to restore blood pressure and, in extreme cases, hemodialysis to remove the drug from the blood.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as stopping suddenly can cause your blood pressure to spike.

While many people tolerate Lisinopril well, some experience side effects as their body adjusts to the medication. The most common side effects include:

• Dry Cough: This is a hallmark side effect of ACE inhibitors, occurring in approximately 3% to 10% of patients. It is typically a persistent, non-productive (dry) tickle in the throat. It is caused by the accumulation of bradykinin in the lungs. This cough usually does not respond to cough suppressants and typically only resolves when the medication is discontinued.
• Dizziness and Lightheadedness: As the drug lowers blood pressure, you may feel dizzy, especially when rising quickly from a sitting or lying position. This is known as orthostatic hypotension.
• Headache: Mild to moderate headaches are frequently reported during the first few weeks of therapy.

• Fatigue and Asthenia: A general feeling of tiredness or weakness.
• Nausea and Diarrhea: Gastrointestinal disturbances may occur but are usually transient.
• Skin Rash: Mild allergic skin reactions or itching.
• Chest Pain: Occasionally reported, though it must be distinguished from the underlying heart condition.
• Hyperkalemia: An increase in blood potassium levels. Symptoms are often absent but can include muscle weakness or heart palpitations.

• Psoriasis Aggravation: Lisinopril may worsen existing psoriasis.
• Taste Disturbance (Dysgeusia): A metallic or salty taste in the mouth.
• Hyponatremia: Low blood sodium levels, which can cause confusion or seizures if severe.
• Impotence: Sexual dysfunction has been reported in a small percentage of male patients.

> Warning: Stop taking Lisinopril and call your doctor or emergency services immediately if you experience any of the following:

• Angioedema: This is a rare but life-threatening allergic reaction. It involves rapid swelling of the face, lips, tongue, throat, or extremities. If the swelling affects the airway (laryngeal edema), it can lead to fatal airway obstruction. This reaction can occur at any time during treatment, even after years of safe use, and is more common in Black patients.
• Liver Toxicity: Symptoms include yellowing of the skin or eyes (jaundice), dark urine, pale stools, and severe abdominal pain. ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis.
• Kidney Failure: Signs include a significant decrease in urine output, swelling in the ankles or feet, and shortness of breath. Lisinopril can cause acute renal failure, especially in patients with pre-existing renal artery stenosis.
• Neutropenia/Agranulocytosis: A severe drop in white blood cell counts, which increases the risk of infection. Seek help for unexplained fever or sore throat.
• Severe Hypotension: Fainting or feeling like you might pass out.

Prolonged use of Lisinopril is generally considered safe and is often necessary for the management of chronic conditions. However, long-term monitoring is required for:

• Renal Function Changes: Over years, some patients may experience a gradual decline in kidney function, especially if they have other conditions like diabetes or are taking other medications that affect the kidneys.
• Electrolyte Imbalance: Chronic suppression of aldosterone can lead to persistent elevations in potassium, which requires dietary management or periodic blood tests.

Fetal Toxicity: Lisinopril carries a strict FDA Black Box Warning regarding its use during pregnancy. When pregnancy is detected, Lisinopril should be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus, particularly during the second and third trimesters. Risks include skull hypoplasia (underdeveloped skull), anuria (lack of urine), renal failure, and limb contractures in the newborn.

Report any unusual symptoms or side effects to your healthcare provider promptly to ensure your treatment remains safe and effective.

Lisinopril is a powerful cardiovascular medication that requires careful medical supervision. It is not suitable for everyone, and certain precautions must be taken to prevent serious adverse events. Patients must be aware that while Lisinopril effectively manages conditions like hypertension and heart failure, it is not a cure. Most patients will need to remain on antihypertensive therapy indefinitely to prevent complications like stroke or heart attack.

WARNING: FETAL TOXICITY

• When pregnancy is detected, discontinue Lisinopril as soon as possible.
• Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
• Exposure to ACE inhibitors during the second and third trimesters has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.
• Oligohydramnios (low amniotic fluid) may also occur, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development.

• Anaphylaxis and Angioedema: As noted previously, angioedema of the face, extremities, lips, tongue, glottis, and/or larynx has been reported. This is a medical emergency. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor.
• Hypotension (Low Blood Pressure): Excessive hypotension is rare in patients with uncomplicated hypertension but is a possibility in patients who are volume-depleted (e.g., those on high-dose diuretics, undergoing dialysis, or suffering from severe vomiting/diarrhea). In heart failure patients, Lisinopril may cause excessive hypotension, which may be associated with oliguria or progressive azotemia.
• Impaired Renal Function: In patients with severe heart failure whose renal function may depend on the activity of the RAAS, treatment with Lisinopril may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. Patients with unilateral or bilateral renal artery stenosis may experience increases in blood urea nitrogen (BUN) and serum creatinine.
• Hyperkalemia: Elevated serum potassium levels can occur. Risk factors include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium.
• Surgery/Anesthesia: In patients undergoing major surgery or during anesthesia with agents that produce hypotension, Lisinopril will block angiotensin II formation secondary to compensatory renin release. This can lead to hypotension that can be corrected by volume expansion.

To ensure safety, your healthcare provider will require periodic laboratory tests, including:

• Serum Creatinine and BUN: To monitor kidney function, especially during the first few weeks of therapy or after dose increases.
• Serum Potassium: To check for hyperkalemia.
• Blood Pressure: Regular monitoring at home and in the clinic to ensure the dose is effective and not causing excessive hypotension.
• White Blood Cell Count: Occasionally monitored in patients with collagen vascular disease (like lupus) or renal impairment to check for neutropenia.

Lisinopril can cause dizziness, especially during the first few days of treatment or when the dose is increased. Do not drive, operate heavy machinery, or engage in dangerous activities until you know how this medication affects you.

Alcohol can enhance the blood-pressure-lowering effect of Lisinopril, which may lead to severe dizziness, lightheadedness, or fainting. It is generally advised to limit alcohol consumption while taking this medication.

Do not stop taking Lisinopril abruptly. While it does not typically cause a 'rebound' effect like some other blood pressure medications (e.g., beta-blockers), your blood pressure will likely return to hypertensive levels, increasing your risk of cardiovascular events. Always consult your doctor before tapering or stopping the medication.

> Important: Discuss all your medical conditions, especially kidney disease, diabetes, and allergies, with your healthcare provider before starting Lisinopril.

• Aliskiren (Tekturna): The use of Lisinopril in combination with aliskiren is strictly contraindicated in patients with diabetes mellitus. This combination significantly increases the risk of renal impairment, hyperkalemia, and severe hypotension.
• Sacubitril/Valsartan (Entresto): Lisinopril must not be administered within 36 hours of switching to or from sacubitril/valsartan. This combination significantly increases the risk of life-threatening angioedema.

• Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene, Amiloride): These drugs increase potassium levels. When taken with Lisinopril, the risk of severe hyperkalemia (which can cause cardiac arrest) is high. If used together, potassium levels must be monitored frequently.
• Potassium Supplements and Salt Substitutes: Most salt substitutes contain potassium chloride instead of sodium chloride. Using these with Lisinopril can lead to dangerously high potassium levels.
• Lithium: ACE inhibitors like Lisinopril can reduce the renal clearance of lithium, leading to toxic levels of lithium in the blood. Frequent monitoring of serum lithium levels is required if these drugs are co-administered.
• NSAIDs (e.g., Ibuprofen, Naproxen, Celecoxib): Non-steroidal anti-inflammatory drugs can reduce the antihypertensive effect of Lisinopril. Furthermore, in patients who are elderly, volume-depleted, or have poor kidney function, the combination can lead to acute kidney failure (the 'Triple Whammy' effect when combined with a diuretic).

• Other Antihypertensives: While often used together intentionally, combining Lisinopril with beta-blockers, calcium channel blockers, or other diuretics increases the risk of hypotension.
• Insulin and Oral Antidiabetics: Lisinopril may increase the blood-sugar-lowering effect of these medications, potentially leading to hypoglycemia (low blood sugar). Blood glucose monitoring should be intensified when starting an ACE inhibitor.
• Gold (Sodium Aurothiomalate): Nitritoid reactions (symptoms include facial flushing, nausea, vomiting, and hypotension) have been reported rarely in patients on therapy with injectable gold and concomitant ACE inhibitor therapy.

• High-Potassium Foods: While a healthy diet is encouraged, excessive consumption of high-potassium foods (like bananas, oranges, and spinach) should be discussed with a doctor, as Lisinopril causes the body to retain potassium.
• Grapefruit: Unlike some other heart medications, Lisinopril does not have a significant interaction with grapefruit juice.
• Dairy: There are no known significant interactions between Lisinopril and dairy products.

• St. John's Wort: May slightly reduce the effectiveness of Lisinopril by affecting overall blood pressure regulation.
• Garlic and Ginger: These have mild natural blood-pressure-lowering properties and may theoretically enhance the effect of Lisinopril, though this is rarely clinically significant.
• Natural Licorice: Can cause sodium retention and potassium loss, which counteracts the effects of Lisinopril.

Lisinopril does not typically interfere with common laboratory tests, but it will affect the results of the Renin-Angiotensin System assessment. It may also cause a false-positive result in some urine ketone tests.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the best way to prevent dangerous drug interactions.

Lisinopril must NEVER be used in the following circumstances:

• History of Angioedema: Any patient who has previously experienced angioedema (swelling of the face, lips, or tongue) related to previous treatment with an ACE inhibitor or for any other reason (hereditary or idiopathic angioedema) must not take Lisinopril. The risk of a fatal recurrence is extremely high.
• Pregnancy: Due to the risk of severe fetal injury and death, Lisinopril is absolutely contraindicated in the second and third trimesters of pregnancy and should be avoided in the first trimester if possible.
• Concomitant use with Aliskiren in Diabetes: As mentioned, this combination increases the risk of kidney failure and stroke.
• Hypersensitivity: Known allergy to Lisinopril or any other ACE inhibitor (e.g., Enalapril, Ramipril, Benazepril).

Conditions requiring careful risk-benefit analysis and intensive monitoring include:

• Aortic Stenosis / Hypertrophic Cardiomyopathy: In patients with obstruction to the outflow of blood from the heart, vasodilators like Lisinopril should be used with extreme caution as they may reduce coronary perfusion.
• Renal Artery Stenosis: In patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, there is an increased risk of acute renal failure.
• Volume Depletion: Patients who are severely dehydrated or have low salt levels due to intense diuretic therapy or dialysis are at high risk for a major drop in blood pressure upon the first dose.
• Autoimmune Diseases: Patients with collagen vascular diseases like systemic lupus erythematosus (SLE) or scleroderma are at a higher risk of developing blood disorders (neutropenia) while taking Lisinopril.

There is a high degree of cross-sensitivity among ACE inhibitors. If a patient has had a serious allergic reaction to another drug ending in '-pril', they should generally not be prescribed Lisinopril. However, there is no cross-sensitivity between ACE inhibitors and other classes of blood pressure medications like Calcium Channel Blockers or Beta-Blockers.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous allergic reactions, before prescribing Lisinopril.

Lisinopril is categorized as Pregnancy Category D (with a Black Box Warning). It is strictly contraindicated in the second and third trimesters. If a patient becomes pregnant while taking Lisinopril, the medication must be stopped immediately. Use during the first trimester is also generally discouraged as some studies suggest a potential risk of congenital malformations, particularly of the cardiovascular and central nervous systems. Women of childbearing age should use effective contraception while on this medication.

It is not known whether Lisinopril is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ACE inhibitors, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Alternative antihypertensive medications with better safety data during breastfeeding (such as Methyldopa or Nifedipine) are often preferred.

Lisinopril is safe and effective for treating hypertension in children aged 6 to 16 years. However, it has not been studied in children with heart failure or in those who have recently had a heart attack. It should not be used in neonates or children with very low kidney function (GFR < 30 mL/min). Long-term effects on growth and development have not been extensively studied, but no specific concerns have emerged in clinical practice.

Clinical studies have not identified overall differences in safety or effectiveness between elderly (65 years and older) and younger patients. However, elderly patients are more likely to have decreased renal function and may be taking multiple other medications (polypharmacy). This increases the risk of drug interactions and side effects like dizziness and falls. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

As Lisinopril is cleared by the kidneys, its half-life increases significantly in patients with renal failure. For patients with a CrCl between 10 and 30 mL/min, the starting dose should be reduced to 5 mg. For those with a CrCl < 10 mL/min or those on dialysis, the starting dose is 2.5 mg. These patients require frequent monitoring of serum creatinine and potassium levels.

Unlike most other ACE inhibitors, Lisinopril is not a prodrug and does not require activation by the liver. Therefore, its pharmacokinetics are not significantly altered in patients with stable hepatic cirrhosis. However, these patients should still be monitored for general safety and potential fluid balance changes.

> Important: Special populations require individualized medical assessment and more frequent monitoring to ensure the safe use of Lisinopril.

Lisinopril is a non-sulfhydryl Angiotensin-Converting Enzyme (ACE) inhibitor. Its primary molecular target is the ACE enzyme, a dicarboxypeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the potent octapeptide vasoconstrictor, angiotensin II. By binding to and inhibiting ACE, Lisinopril reduces the concentration of angiotensin II in the plasma and tissues.

This inhibition leads to:

1. 1Decreased Vasoconstriction: Lower levels of angiotensin II result in the relaxation of vascular smooth muscle, leading to decreased systemic vascular resistance.
2. 2Decreased Aldosterone Secretion: Reduced angiotensin II leads to lower aldosterone levels, which decreases sodium and water reabsorption in the distal tubules of the kidney.
3. 3Increased Bradykinin Levels: ACE also degrades bradykinin (a vasodilator). Inhibition of ACE increases bradykinin levels, which contributes to the antihypertensive effect through the release of nitric oxide and prostacyclins.

• Onset of Action: The antihypertensive effect usually begins within 1 hour of oral administration.
• Peak Effect: The maximum reduction in blood pressure occurs approximately 6 to 7 hours after dosing.
• Duration: A single dose provides a clinically significant blood-pressure-lowering effect for 24 hours, facilitating once-daily dosing.
• Tolerance: There is no evidence of the development of tolerance (diminishing effect) with long-term use of Lisinopril.

| Parameter | Value |

|---|---|

| Bioavailability | ~25% (range 6-60%) |

| Protein Binding | 0% (only binds to ACE) |

| Half-life | ~12 hours (accumulation half-life) |

| Tmax | ~7 hours |

| Metabolism | None (Excreted unchanged) |

| Excretion | Renal 100% |

• Molecular Formula: C21H31N3O5·2H2O
• Molecular Weight: 441.52 g/mol
• Solubility: Soluble in water and methanol; sparingly soluble in ethanol.
• Structure: It is a synthetic peptide derivative, specifically the lysine-analog of enalaprilat.

Lisinopril is classified as an Angiotensin-Converting Enzyme Inhibitor [EPC]. It belongs to the same therapeutic family as Enalapril, Ramipril, and Captopril. Within the broader category of antihypertensives, it is considered a first-line agent for the treatment of hypertension and heart failure, particularly in patients with diabetes or chronic kidney disease.